Detalhe da pesquisa
1.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Blood
; 142(13): 1131-1142, 2023 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363833
2.
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.
EClinicalMedicine
; 63: 102167, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37680948
3.
A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma.
Blood Adv
; 7(19): 5911-5924, 2023 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552109
4.
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Lancet Haematol
; 9(3): e190-e199, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35240075
5.
Hematopoietic stem and progenitor cells are differentially mobilized depending on the duration of Flt3-ligand administration.
Haematologica
; 95(7): 1061-7, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20081057
6.
Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.
Haematologica
; 100(3): e90-2, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25425692
7.
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.
Blood Adv
; 3(17): 2642-2652, 2019 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31506282
8.
Improving the identification of frail elderly newly diagnosed multiple myeloma patients.
Leukemia
; 35(9): 2715-2719, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33589752
9.
Involvement of proteases in cytokine-induced hematopoietic stem cell mobilization.
Ann N Y Acad Sci
; 1044: 60-9, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15958698
10.
Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
Leuk Lymphoma
; 54(4): 874-7, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22971215
11.
Serpina1 is a potent inhibitor of IL-8-induced hematopoietic stem cell mobilization.
Proc Natl Acad Sci U S A
; 103(5): 1469-74, 2006 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-16432201
12.
Reduced stem cell mobilization in mice receiving antibiotic modulation of the intestinal flora: involvement of endotoxins as cofactors in mobilization.
Blood
; 103(1): 340-6, 2004 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12969972
13.
Enhancement of G-CSF-induced stem cell mobilization by antibodies against the beta 2 integrins LFA-1 and Mac-1.
Blood
; 100(1): 327-33, 2002 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12070044